Cosentyx is a biologic drug used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting a specific protein that causes inflammation in the body. The drug is generally well-tolerated, but it is important to consider how it affects elderly patients.

One study found that elderly patients (over the age of 65) who were treated with Cosentyx had similar efficacy and safety outcomes as younger patients. The study followed patients for up to 52 weeks and found that there were no significant differences in the rate of adverse events or serious adverse events between the two groups [2].

Another study looked specifically at the safety and efficacy of Cosentyx in elderly patients with psoriasis. The study found that the drug was effective in reducing symptoms of psoriasis in this population and was generally well-tolerated. However, the study did note that elderly patients may be at a higher risk for certain adverse events, such as infections, and should be monitored closely [3].

It is important to note that individual patient factors, such as overall health and other medications, can also impact how Cosentyx affects elderly patients. Therefore, it is important for healthcare providers to carefully consider each patient's individual situation when deciding whether to prescribe Cosentyx.

Sources:
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847154/
[3] https://pubmed.ncbi.nlm.nih.gov/29404966/
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX